The indolent natural history of essential thrombocythemia: A challenge to new drug development

Mayo Clinic Proceedings

Volumn 80, Issue 1, 2005, Pages 97-98

  Tefferi, Ayalew ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA; NEW DRUG; PIPOBROMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTICOAGULATION; CARDIOMYOPATHY; CLINICAL TRIAL; DRUG EFFICACY; DRUG PREFERENCE; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HISTORY OF MEDICINE; HUMAN; MYELOFIBROSIS; MYELOID METAPLASIA; NEUROPATHY; NOTE; THROMBOCYTHEMIA;

EID: 11344257365     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)62964-9     Document Type: Note

References (33)

1. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121-131.
2. Epstein E, Goedel A. Hämorrhagische thrombocythamie bei vascularer schrumpfmilz. Virchows Arch A Pathol Anat Histopathol. 1934;293:233-236.
3. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
4. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
5. Finazzi G, Ruggeri M, Rodeghiero F, Baibui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577-583.
6. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772-777.
7. Green A, Campbell P, Buck G, et al. The Medical Research Council PT1 trial in essential thrombocythemia [abstract]. Blood. 2004;104(11). Abstract 6.
8. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549-556.
9. Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999;78:539-543.
10. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150-154.
11. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
12. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.
13. Tefferi A, Solberg LA, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med. 2000;109:141-149.
14. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215-232.
15. Mazzucconi MG, Redi R, Bernasconi S, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica. 2004;89:1306-1313.
16. Anegrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69-76.
17. Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003;98:100-109.
18. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998;83:1205-1213.
19. De Sanctis V, Mazzucconi MG, Spadea A, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol. 2003;123:517-521.
20. Passamonti F, Malabarba L, Orlandi E, et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol. 2002;116:855-861.
21. Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer. 2004;101:2239-2246.
22. Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematoiogica. 2004;89:1394-1395.
23. Vardizer Y, Linhart Y, Loewenstein A, Garzozi H, Mazawi N, Kesler A. Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol. 2003;23:256-259.
24. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863-866.
25. Birgegard G, Bjorkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89:520-527.
26. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22-28.
27. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663.
28. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis [letter]. Blood. 2003;101:3749.
29. Randi ML, Fabris F, Girolami A. Second malignancies in patients with essential thrombocythaemia [letter]. Br J Haematol. 2002;116:923-924.
30. Gugliotta L, Bulgarelli A, Tieghi A, et al. Bone marrow biopsy and aspirate evaluation in 90 patients with essential thrombocythemia treated with PEG interferon alpha-2b: preliminary results [abstract]. Blood. 2004;104(11). Abstract 1523.
31. Finazzi G, Caruso V, Marchioli R, et al, ECLAP Investigators. Acute leukemia in polycythemia vera: an analysis of 1,638 patients enrolled in a prospective observational study. Blood. 2004 December 7 [Epub ahead of print]. Available at: www.bloodjournal.org/cgi/reprint/2004-09-3426v1.
32. Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythemia? [letter]. Blood. 1998;92:1459-1460.
33. Cheung MC, Hicks LK, Pendergrast J. Thrombocytosis [letter).N Engl J Med. 2004;350:2524-2525.